Risk Factors Associated with Thrombus Development Following Pharmacologic Anticoagulation Reversal with Coagulation Factor Xa [Recombinant], Inactivated-zhzo
{{output}}
Background: Andexanet alfa (AA), a recombinant coagulation factor Xa, is approved as an antidote for the treatment of bleeding secondary to rivaroxaban and apixaban. While thromboembolism may serve as a risk with reversal of ther... ...
